Sevincok Levent, Topuz Ayse
Department of Psychiatry, Adnan Menderes University, Aydin, Turkey.
J Clin Psychopharmacol. 2003 Oct;23(5):448-50. doi: 10.1097/01.jcp.0000088900.24613.f2.
Some studies have shown that low dose of neuroleptic addition to ongoing antiobsessive treatment might be effective in treatment resistant obsessive-compulsive disorder (OCD). The primary purpose of this study was to evaluate the efficacy of low-dose quetiapine in clomipramine and serotonin reuptake inhibitor-refractory obsessive-compulsive disorder patients.
Eight obsessive-compulsive disorder patients who were resistant to treatment after 2 or more inadequate trials with clomipramine or serotonin reuptake inhibitor were admitted to the study. The patients were administrated on open trial of quetiapine at daily dose of 150 mg. Treatment response was assessed using the Yale-Brown Compulsive Scale and the Clinical Global Impressions Scale.
Only 2 patients were partial responders, with Yale-Brown Compulsive Scale score decreases of 28% and 29%.
The results of this preliminary open trial suggest that low dose of quetiapine may not be effective in treatment-resistant obsessive-compulsive disorder patients. Larger placebo-controlled trials are needed to investigate the clinical efficacy of quetiapine addition at low doses to antiobsessive treatment in treatment-refractory obsessive-compulsive disorder.
一些研究表明，在持续的抗强迫治疗中添加低剂量抗精神病药物可能对难治性强迫症（OCD）有效。本研究的主要目的是评估低剂量喹硫平对氯米帕明和5-羟色胺再摄取抑制剂难治性强迫症患者的疗效。
8例在接受2次或更多次氯米帕明或5-羟色胺再摄取抑制剂治疗无效后仍对治疗有抵抗的强迫症患者被纳入研究。患者接受喹硫平每日150mg的开放试验。使用耶鲁-布朗强迫量表和临床总体印象量表评估治疗反应。
仅2例患者为部分缓解者，耶鲁-布朗强迫量表评分分别降低了28%和29%。
这项初步开放试验的结果表明，低剂量喹硫平可能对难治性强迫症患者无效。需要开展更大规模的安慰剂对照试验，以研究在难治性强迫症的抗强迫治疗中添加低剂量喹硫平的临床疗效。
